<DOC>
	<DOCNO>NCT02978482</DOCNO>
	<brief_summary>A Phase 1/2 Open-label , Multi-center Study Evaluate Safety , Tolerability , Pharmacokinetics , Anti-tumor Activity Durvalumab ( MEDI4736 ) combination tremelimumab Chinese Patients Advanced Malignancies</brief_summary>
	<brief_title>A Phase 1/2 Study Durvalumab ( MEDI4736 ) Tremelimumab Chinese Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Male female , age least 18 year For Phase 1 PK cohort : Patients histologically cytologically confirm advanced and/or metastatic solid tumor HCC refractory intolerable exist standard treatment For Phase 2 cohort : For nasopharyngeal carcinoma : Patients histologically cytologically confirm nasopharyngeal carcinoma must locally advance metastatic disease progress least 1 chemotherapy regimen without radiotherapy . ONLY FOR PHASE 2 PORTION : mandatory tumor sample No prior exposure immunemediated therapy include , limited , anti CTLA4 , antiPD1 , antiPDL1 , antiprogrammed cell death ligand 2 ( antiPDL2 ) antibody , exclude therapeutic anticancer vaccine . Life expectancy ≥12 week Day 1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 At least 1 lesion accurately measure baseline , suitable repeat measurement per RECIST 1.1 guideline . Adequate organ marrow function Hemoglobin ≥9 g/dL Absolute neutrophil count ≥1.0 × 109 /L Platelet count ≥75 × 109/L Total serum bilirubin ≤1.5×upper limit normal ( ULN ) ALT AST ≤2.5×ULN ; patient hepatic metastasis , ALT AST ≤5×ULN Calculated creatinine clearance &gt; 40 mL/min determine CockcroftGault ( use actual body weight ) , measure 24hour urine collection determination creatinine clearance . Evidence postmenopausal status , negative urinary serum pregnancy test female premenopausal patient . Any concurrent chemotherapy , IP , biologic , hormonal therapy cancer treatment . Concurrent use hormonal therapy noncancerrelated condition ( eg , hormone replacement therapy ) acceptable . Note : Local treatment isolate lesion palliative intent acceptable ( eg , local surgery radiotherapy ) . Receipt last dose approve ( market ) anticancer therapy ( chemotherapy , target therapy , biologic therapy , mAbs , etc ) within 21 day prior first dose study treatment . If sufficient washout time occur due schedule PK property agent , long washout period require , agree upon AstraZeneca Investigator . Radiotherapy treatment 30 % bone marrow wide field radiation within 4 week first dose study drug . Major surgical procedure ( defined Investigator ) within 28 day prior first dose IP . Note : Local surgery isolate lesion palliative intent acceptable . History allogenic organ transplantation Any unresolved toxicity National Cancer Institute ( NCI ) CTCAE Version 4.03 Grade ≥2 previous anticancer therapy Active prior document autoimmune inflammatory disorder ( include inflammatory bowel disease [ eg , colitis Crohn 's disease ] , diverticulitis [ exception diverticulosis ] , celiac disease , systemic lupus erythematosus , Sarcoidosis syndrome , Wegener syndrome [ granulomatosis polyangiitis ] , Graves ' disease , rheumatoid arthritis , hypophysitis , uveitis , etc ) . Uncontrolled intercurrent illness , include limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , interstitial lung disease , serious chronic gastrointestinal condition associate diarrhea , psychiatric illness/social situation would limit compliance study requirement , substantially increase risk incur AEs compromise ability patient give write informed consent History another primary malignancy History leptomeningeal carcinomatosis Brain metastases spinal cord compression unless asymptomatic treat stable steroid anticonvulsant least 14 day prior study treatment . QT interval correct heart rate use Fridericia 's formula ( QTcF ) ≥470 m calculate . History active primary immunodeficiency Active infection include tuberculosis , hepatitis B , hepatitis C , human immunodeficiency virus . Current prior use immunosuppressive medication within 14 day first dose durvalumab ( MEDI4736 ) tremelimumab . Receipt live , attenuated vaccine within 30 day prior first dose IP . Female patient pregnant breastfeed male female patient reproductive potential willing employ effective birth control screen 180 day last dose durvalumab ( MEDI4736 ) plus tremelimumab combination therapy 90 day last dose durvalumab ( MEDI4736 ) monotherapy . Known allergy hypersensitivity IP IP excipient , humanize mAbs Prior randomisation treatment previous durvalumab ( MEDI4736 ) and/or tremelimumab clinical study regardless treatment arm assignment NSCLC patient history interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>